Skip to Content
Merck
  • A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.

A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.

Parkinsonism & related disorders (2014-09-16)
Bing Han, Hui Juan Jin, Mei Ying Song, Tian Wang, Hua Zhao
ABSTRACT

Parkinson's disease (PD) is a progressive neurodegenerative movement disorder that is caused predominantly by the degeneration of the nigrostriatal dopaminergic pathway. Lateral habenula (LHb) has efferent projections that terminate in the substantia nigra pars compacta (SNpc) and electrical stimulation of the LHb effectively suppresses the activity of dopamine-containing neurons in the SNpc. This study was aimed to investigate whether LHb lesions can ameliorate the syndromes of PD via affecting the activities of SNpc neurons in 6-hydroxydopamine (6-OHDA)-induced PD model rats. Concentrations of dopamine (DA) and its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the striatum, which is the area projected by the SNpc dopaminergic neurons were assayed by high-performance liquid chromatography (HPLC) coupled with fluorescence detection. The immunohistochemical method was applied to detect the numbers of tyrosine hydroxylase (TH)-positive cells in the substantia nigra. The results showed that LHb lesions induced a significant reduction in apomorphine-induced rotational behavior. The DA, DOPAC and HVA levels in the striatum of PD model rats were increased by the LHb lesions. Therefore, we speculate that the LHb lesions induced a significant amelioration in motor disorders via increasing the DA levels in the striatum, which may lead to a potential therapeutic strategy for the treatment of PD.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
3,4-Dihydroxyphenylacetic acid, 98%
Sigma-Aldrich
Homovanillic acid, Fluorimetric reagent
Sigma-Aldrich
Ethylenediaminetetraacetic acid solution, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Supelco
Perchloric acid concentrate, 0.01 M HClO4 in water (0.01N), eluent concentrate for IC
Sigma-Aldrich
R-(−)-Apomorphine hydrochloride hemihydrate, calcined, ≥98.5% (with NaOH, titration)
Sigma-Aldrich
Perchloric acid, ACS reagent, 60%
Sigma-Aldrich
Perchloric acid, puriss. p.a., ACS reagent, packed in coated, shock- and leak-protected glass bottle, ≥60% (T)
Apomorphine hydrochloride hemihydrate, European Pharmacopoeia (EP) Reference Standard
Supelco
Desipramine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Homovanillic acid, analytical standard
Supelco
3,4-Dihydroxyphenylacetic acid, analytical standard
Sigma-Aldrich
Perchloric acid, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 70.0-72.0%
Sigma-Aldrich
Perchloric acid, ACS reagent, 70%
Desipramine hydrochloride, European Pharmacopoeia (EP) Reference Standard
USP
Desipramine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Ethylenediaminetetraacetic acid, 99.995% trace metals basis
Sigma-Aldrich
Ethylenediaminetetraacetic acid, purified grade, ≥98.5%, powder
Sigma-Aldrich
Ethylenediaminetetraacetic acid, anhydrous, BioUltra, ≥99% (titration)
Sigma-Aldrich
Ethylenediaminetetraacetic acid, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
6-Hydroxydopamine hydrochloride, ≥97% (titration), powder
Sigma-Aldrich
Desipramine hydrochloride, ≥98% (TLC), powder
Sigma-Aldrich
Ethylenediaminetetraacetic acid, ≥98.0% (KT)
Sigma-Aldrich
Ethylenediaminetetraacetic acid, BioUltra, ≥99.0% (KT)
Sigma-Aldrich
Perchloric acid, 70%, 99.999% trace metals basis